Arrhythmia Clinical Trial
The bile acids has been demonstrated to cause arrhythmia and abnormal calcium dynamics in cultured neonatal rat cardiomyocytes. Bile acids may alter maternal cardiomyocyte function like fetus.Increased P-wave duration and P-wave dispersion have been reported in various clinical settings. The investigators hypothesized that PWD and p wave duration may affect in pregnancy with ICP.
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disease. The most
frequent laboratory abnormality is elevation of serum bile acid levels in ICP.
Bile acids increases both maternal and fetal circulation in ICP. The bile acids has been
demonstrated to cause arrhythmia and abnormal calcium dynamics in cultured neonatal rat
cardiomyocytes. Raised maternal bile acid levels have been associated with fetal distress
and arrhytmia in fetus.
P-wave dispersion (PWD) is defined as the difference between the maximum and the minimum
P-wave durations measured on a 12-lead surface electrocardiogram (ECG). Increased P-wave
duration and PWD have been reported in various clinical settings, including atrial flutter,
coronary artery disease, hypertension, rheumatic mitral stenosis, mitral annular
calcification, obstructive sleep apnea, and obesity.
So the investigators think that bile acids may alter maternal cardiomyocyte function as
fetus. The investigators hypothesized that PWD and p wave duration may affect in pregnancy
with ICP.
The aim of this study is to investigate maternal P-wave duration and dispersion changes in
pregnant women with intrahepatic cholestasis of pregnancy .
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05048602 -
Drug-induced Brugada Syndrome Research Database
|
||
| Completed |
NCT05053243 -
Clinical Validation of the AliveCor Kardia 12L and 6L Devices
|
N/A | |
| Completed |
NCT01913561 -
The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection
|
N/A | |
| Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
| Completed |
NCT01396226 -
A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients
|
Phase 2 | |
| Terminated |
NCT00721149 -
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study
|
Phase 3 | |
| Terminated |
NCT00624520 -
Mental Stress Reduction in Defibrillator Patients
|
Phase 3 | |
| Completed |
NCT00756886 -
Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study
|
N/A | |
| Completed |
NCT00510029 -
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
|
Phase 1 | |
| Completed |
NCT00578617 -
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
|
N/A | |
| Active, not recruiting |
NCT00135174 -
Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The Followpace Study
|
N/A | |
| Completed |
NCT00119847 -
Electrophysiological Effects of Late PCI After MI
|
N/A | |
| Completed |
NCT00035490 -
Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
|
Phase 3 | |
| Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
| Completed |
NCT00004560 -
Public Access Defibrillation (PAD) Community Trial
|
Phase 3 | |
| Completed |
NCT01076361 -
Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study
|
N/A | |
| Recruiting |
NCT00138931 -
Genetics of Cardiovascular and Neuromuscular Disease
|
||
| Completed |
NCT00622453 -
Arrhythmias in Myotonic Muscular Dystrophy
|
N/A | |
| Completed |
NCT01076348 -
Model 4965 Post-Approval Study
|
||
| Completed |
NCT00000531 -
Antiarrhythmics Versus Implantable Defibrillators (AVID)
|
Phase 3 |